Why is Marksans Pharma falling/rising?

As of 19-Sep, Marksans Pharma Ltd is currently priced at 178.90, reflecting a slight increase of 0.2 (0.11%). The stock has shown a performance of +3.41% over the past week, which is significantly better than the Sensex's +0.88% during the same period. However, the stock has underperformed over the longer term, with a -3.01% return over the past month and a substantial -39.61% year-to-date decline. Today's price summary indicates that the stock is performing in line with its sector, with a delivery volume increase of 12.93% compared to the 5-day average, suggesting rising investor participation. Positive factors include high management efficiency with a return on equity (ROE) of 17.66% and a low debt-to-equity ratio, which may support investor confidence. However, negative factors such as poor long-term growth, declining operating profits, and a high price-to-book value ratio indicate underlying challenges that could be affecting the stock's performance.
Broader market context shows that while Marksans Pharma has seen a positive short-term return, it has significantly lagged behind the market over the past year, with a return of -35.31% compared to the BSE500's -1.96%. This underperformance highlights the stock's struggles relative to broader market trends, despite some recent positive movements. The high institutional holdings at 25.38% suggest that more sophisticated investors are involved, which could provide some stability, but the overall negative sentiment due to the company's recent financial results and poor growth prospects may continue to weigh on the stock's price.